Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Part 1: SAD RO7033877
SAD RO7033877 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo | PLACEBO_COMPARATOR | Saline solution, given as a minimum of a 2 hour infusion |
| Part 1: RO7033877 | EXPERIMENTAL | Single ascending dose |
| Part 2: RO7033877 | EXPERIMENTAL | Single-dose 4-way crossover |
| Name | Type | Description |
|---|---|---|
| Part 1: SAD RO7033877 | DRUG | Single dose |
| Part 1: SAD placebo | DRUG | Single dose |
| Part 2: Treatment A, RO7033877 | DRUG | Single dose RO7033877 and moxifloxacin placebo |
| Part 2: Treatment B, RO7033877 | DRUG | Single dose RO7033877 and moxifloxacin placebo |
| Part 2: Treatment C, moxifloxacin | DRUG | Single dose moxifloxacin and RO7033877 placebo |
| Part 2: Treatment D, RO7033877 and moxifloxacin placebo | DRUG | Single dose moxifloxacin placebo and RO7033877 placebo |
Inclusion Criteria: * Healthy male or female of non-childbearing potential participants, 18 to 65 years of age, inclusive * Healthy status is defined as the absence of evidence of any clinically significant, active, or chronic disease following a detailed medical and surgical history, a complete ph...